Allarity Therapeutics (ALLR) News Today $1.01 -0.04 (-3.81%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.02 +0.01 (+1.49%) As of 07/15/2025 06:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALLR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Allarity Therapeutics, Inc.: Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP Platform UtilizationJuly 15 at 11:26 AM | finanznachrichten.deAllarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform UtilizationJuly 15 at 11:26 AM | finance.yahoo.comAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief ...July 9, 2025 | seekingalpha.comAllarity Therapeutics Appoints Jeff Ervin as New Chief Financial OfficerJuly 9, 2025 | nasdaq.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerJuly 8, 2025 | finanznachrichten.deAllarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial OfficerJuly 7, 2025 | globenewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP Companion Diagnostic - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deAllarity Therapeutics Announces Acceptance of Patent Application for Stenoparib DRP® in Australia - NasdaqJuly 2, 2025 | nasdaq.comAllarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion DiagnosticJune 30, 2025 | finance.yahoo.comAllarity Therapeutics Doses Second Patient in Phase 2 Trial of Stenoparib for Ovarian Cancer - NasdaqJune 29, 2025 | nasdaq.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian CancerJune 27, 2025 | finanznachrichten.deAllarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian CancerJune 27, 2025 | globenewswire.comAllarity Therapeutics Appoints Jesper Høiland to Board of Directors, Succeeding Joseph VazzanoJune 13, 2025 | nasdaq.comAllarity Therapeutics Announces Changes to Board of DirectorsJune 11, 2025 | globenewswire.comAllarity announces first patient enrolled in Phase 2 trial of stenoparibJune 2, 2025 | msn.comAllarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian CancerJune 2, 2025 | finance.yahoo.comAllarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial EnrollmentMay 9, 2025 | globenewswire.comAllarity unveils new multiple myeloma treatment predictorApril 26, 2025 | investing.comAllarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025April 26, 2025 | finance.yahoo.comAllarity Therapeutics Restructures Board of DirectorsApril 16, 2025 | tipranks.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. ...April 14, 2025 | gurufocus.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmApril 14, 2025 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateApril 2, 2025 | finanznachrichten.deAllarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business UpdateMarch 31, 2025 | markets.businessinsider.comAllarity Therapeutics probes potential stock manipulationMarch 26, 2025 | uk.investing.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 25, 2025 | prnewswire.comAllarity launches effort to combat potential illegal naked short sellingMarch 24, 2025 | markets.businessinsider.comAllarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its SharesMarch 24, 2025 | markets.businessinsider.comALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 19, 2025 | prnewswire.comAllarity announces presentation from Phase 2 trial with stenoparib monotherapyMarch 17, 2025 | markets.businessinsider.comALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law FirmMarch 14, 2025 | prnewswire.comAllarity Therapeutics, Inc.: Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionMarch 14, 2025 | finanznachrichten.deAllarity sees cash runway into 2026March 14, 2025 | markets.businessinsider.comAllarity announces final settlement with SEC including $2.5M civil penaltyMarch 13, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange CommissionMarch 13, 2025 | globenewswire.comAllarity announes Phase 2 trial of stenoparib with temozolomideMarch 6, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans AdministrationMarch 6, 2025 | globenewswire.comAllarity announces board authorization of $5M share repurchase programMarch 3, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase ProgramMarch 3, 2025 | finance.yahoo.comAllarity announces dismissal of securities class action lawsuitFebruary 26, 2025 | markets.businessinsider.comAllarity Therapeutics Announces Dismissal of Securities Class Action LawsuitFebruary 26, 2025 | globenewswire.comAllarity to begin enrollments for Phase 2 protocol to advance stenoparibFebruary 24, 2025 | markets.businessinsider.comAllarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer PatientsFebruary 24, 2025 | globenewswire.comAllarity Therapeutics advances ovarian cancer drug trialFebruary 6, 2025 | msn.comAllarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian CancerFebruary 6, 2025 | globenewswire.comAllarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SECJanuary 30, 2025 | globenewswire.comAllarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff MotionDecember 6, 2024 | globenewswire.comAllarity reports progress in Phase 2 stenoparib trialNovember 18, 2024 | markets.businessinsider.comAllarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate AdvancementsNovember 18, 2024 | globenewswire.comAllarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational HighlightsNovember 14, 2024 | markets.businessinsider.com Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLR Media Mentions By Week ALLR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLR News Sentiment▼0.760.97▲Average Medical News Sentiment ALLR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLR Articles This Week▼54▲ALLR Articles Average Week Get Allarity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Achilles Therapeutics News PDS Biotechnology News ImmunoPrecise Antibodies News Oncobiologics News INmune Bio News Opus Genetics News NRx Pharmaceuticals News VistaGen Therapeutics News Unicycive Therapeutics News ImmuCell News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLR) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allarity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allarity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALLR Stock Alerts